BioMarin pharmaceutical

0:05:19

BioMarin Pharmaceutical CEO: Treating Hemophilia | Mad Money | CNBC

0:01:34

BioMarin Pharmaceutical CEO on the company's drug pricing strategy

0:06:14

BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC

0:07:25

BioMarin CEO expects 'substantial' profitability after FDA approval of hemophilia drug

0:01:06

The BioMarin 8: Operating Principles That Guide Our Work

0:01:37

Commitment to Patients: Kendra's Story

0:06:01

BioMarin Pharmaceutical CEO: Close to a Cure? | Mad Money | CNBC

0:01:20

BMRN Stock (Biomarin Pharmaceutical stock analysis) BMRN STOCK PREDICTION BMRN STOCK analysis BMRN

0:03:20

Mike's Trade: Biomarin (BMRN)

0:05:12

BioMarin Pharmaceuticals CEO | Mad Money | CNBC

0:16:30

BioMarin

0:57:32

Martin Shkreli Analyse Biomarin Stock (Full Excel Valuation)

0:06:50

BioMarin CEO: There are biotech companies 'that probably should not be on the market today’

0:07:17

BioMarin CEO: Rare Treatments, High Costs | Mad Money | CNBC

0:06:57

BioMarin Pharmaceutical CEO: Substantial Profits Ahead | Mad Money | CNBC

0:02:41

BioMarin CEO: Study results for hemophilia gene therapy are as 'good as we could hope'

0:08:11

Finding Tomorrows Trailer

0:05:55

BioMarin CEO Jean-Jacques Bienaimé: Pipeline Profits?| Mad Money | CNBC

0:21:32

Market Ends Grim Year On Sour Note; Celsius, Deere, Biomarin in Focus | Stock Market Today

0:02:53

Cramer's lightning round: I would hold onto Biomarin Pharmaceutical

0:00:55

Meet Ganesh Vedantham

0:00:53

Jean-Jacques Bienaimé, Chief Executive Officer, BioMarin Pharmaceutical Inc.

0:13:53

FDA's approval of BioMarin's Roctavian's highlights challenges and opportunities in Gene Therapy

0:00:30

🔴 BioMarin Pharmaceutical Inc. BMRN Stock Trading Facts 🔴